Lynparza

ASCO: AstraZeneca guns for wider ovarian cancer market with Imfinzi-Lynparza combo. Will the FDA buy the plan?
ASCO: AstraZeneca guns for wider ovarian cancer market with Imfinzi-Lynparza combo. Will the FDA buy the plan?
Fierce Pharma
ASCO 2023
AstraZeneca
Lynparza
Imfinzi
ovarian cancer
Flag link:
FDA clears narrow use of Lynparza in prostate cancer, continuing ‘shift’ on PARP drugs
FDA clears narrow use of Lynparza in prostate cancer, continuing ‘shift’ on PARP drugs
BioPharma Dive
AstraZeneca
Merck
Lynparza
prostate cancer
FDA
Flag link:
AstraZeneca reports positive results from endometrial cancer therapy trial
AstraZeneca reports positive results from endometrial cancer therapy trial
Clinical Trials Arena
AstraZeneca
endometrial cancer
clinical trials
Imfinzi
Lynparza
Flag link:
AstraZeneca's drug combo shows positive results in late-stage cancer trial
AstraZeneca's drug combo shows positive results in late-stage cancer trial
Reuters
ASCO 2023
AstraZeneca
Imfinzi
Lynparza
endometrial cancer
Flag link:
With negative FDA panel vote, AstraZeneca's Lynparza looks set for narrow nod in prostate cancer
With negative FDA panel vote, AstraZeneca's Lynparza looks set for narrow nod in prostate cancer
Fierce Pharma
AstraZeneca
Merck
Lynparza
metastatic castration-resistant prostate cancer
Flag link:
FDA Questions Efficacy of Merck-AstraZeneca’s Lynparza Ahead of Adcomm
FDA Questions Efficacy of Merck-AstraZeneca’s Lynparza Ahead of Adcomm
BioSpace
Merck
AstraZeneca
FDA
Lynparza
metastatic castration-resistant prostate cancer
Flag link:
Trailing AstraZeneca and Merck, Junshi reports phase 3 ovarian cancer success for Lynparza rival
Trailing AstraZeneca and Merck, Junshi reports phase 3 ovarian cancer success for Lynparza rival
Fierce Biotech
Junshi Biosciences
PARP inhibitors
ovarian cancer
Merck
AstraZeneca
Lynparza
Flag link:
AstraZeneca's Lynparza-Imfinzi combo clears PhIII trial in ovarian cancer
AstraZeneca's Lynparza-Imfinzi combo clears PhIII trial in ovarian cancer
Endpoints
AstraZeneca
Lynparza
Imfinzi
ovarian cancer
clinical trials
Flag link:
FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs
FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs
BioPharma Dive
Merck
AstraZeneca
Lynparza
FDA
PARP inhibitors
Flag link:
AstraZeneca, Merck's Lynparza to face FDA panel in prostate cancer bid as PARP scrutiny escalates
AstraZeneca, Merck's Lynparza to face FDA panel in prostate cancer bid as PARP scrutiny escalates
Fierce Pharma
AstraZeneca
Merck
Lynparza
FDA
prostate cancer
Flag link:
AstraZeneca, Merck's Lynparza wins EU nod in advanced prostate cancer right after FDA delay
AstraZeneca, Merck's Lynparza wins EU nod in advanced prostate cancer right after FDA delay
Fierce Pharma
AstraZeneca
Merck
Lynparza
Europe
prostate cancer
advanced prostate cancer
Flag link:
AstraZeneca, Merck hit with 3-month delay for Lynparza's FDA filing in first-line prostate cancer
AstraZeneca, Merck hit with 3-month delay for Lynparza's FDA filing in first-line prostate cancer
Fierce Pharma
AstraZeneca
Merck
Lynparza
FDA
metastatic castration-resistant prostate cancer
Flag link:
AstraZeneca, Merck withdraw Lynparza's late-line ovarian cancer nod amid PARP inhibitor death concerns
AstraZeneca, Merck withdraw Lynparza's late-line ovarian cancer nod amid PARP inhibitor death concerns
Fierce Pharma
AstraZeneca
Merck
Lynparza
ovarian cancer
Flag link:
Merck to stop Phase 3 trial of Lynparza drug in colorectal cancer for futility
Merck to stop Phase 3 trial of Lynparza drug in colorectal cancer for futility
Seeking Alpha
Merck
clinical trials
Lynparza
colorectal cancer
Flag link:
ASCO: Merck's Keytruda combo data could spark hope for lymphoma patients who lack options
ASCO: Merck's Keytruda combo data could spark hope for lymphoma patients who lack options
Fierce Biotech
ASCO 2022
Merck
Keytuda
Lynparza
Lenvima
Flag link:
FDA clears AstraZeneca, Merck drug to treat some genetic breast cancers early
FDA clears AstraZeneca, Merck drug to treat some genetic breast cancers early
BioPharma Dive
AstraZeneca
Merck
Lynparza
genetic breast cancer
FDA
Flag link:
ASCO-GU – prostate cancer PARPS move to the front line
ASCO-GU – prostate cancer PARPS move to the front line
EP Vantage
prostate cancer
ASCO-GU
PARP inhibitors
Lynparza
Zejula
Rubraca
Talzenna
biomarkers
AstraZeneca
Merck
GSK
JNJ
Clovis Oncology
Flag link:
AstraZeneca/Merck come out of ASCO GU with a big win over J&J in battle over prostate cancer franchises
AstraZeneca/Merck come out of ASCO GU with a big win over J&J in battle over prostate cancer franchises
Endpoints
AstraZeneca
Merck
JNJ
ASCO
prostate cancer
Lynparza
Flag link:
Go or no go? Roche’s fresh start for a new year
Go or no go? Roche’s fresh start for a new year
EP Vantage
FDA
Roche
Novartis
Pfizer
AstraZeneca
Cibinqo
Lynparza
Tezspire
Vyvgart
faricimab
Flag link:
FDA grants priority review to AstraZeneca’s sNDA for breast cancer therapy
FDA grants priority review to AstraZeneca’s sNDA for breast cancer therapy
Pharmaceutical Business Review
FDA
AstraZeneca
Lynparza
BRCA-mutant breast cancer
Flag link:

Pages